Innovative Mechanobiology-based Genetic Medicines
Genetic
Cardiomyopathies
Genetic cardiomyopathies is a huge unmet medical need.
Genetic cardiomyopathies are monogenic heart conditions where disease is predominantly caused by mutations in genes that play a role in cardiac force transmission. Mutations in more than 30 genes are known to cause genetic cardiomyopathies, with most mutations inherited autosomal dominantly, meaning that patients have both a normal and a mutant copy of the disease-causing gene. This renders a traditional gene replacement approach infeasible for most of these mutations. Nuevocor is pioneering a functional approach where we leverage our PrOSIA platform to elucidate the disease mechanism and develop targeted therapies that treat the root cause of disease.
Mechanobiology Approach
Nuevocor's strength lies in our innovative PrOSIA mechanobiology platform.
Nuevocor's PrOSIA mechanobiology platform gives us unprecedented insights into biomechanical root cause of many genetic cardiomyopathies. This enables us to design genetic medicines that target causal biomechanical pathways shared among multiple genetic cardiomyopathies. With this, we go beyond traditional gene replacement therapy, which treats single gene mutations. We consider ourselves at the forefront of a new generation of genetic medicine companies pioneering such an innovative pathway-specific approach.
